rs1400121541
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_183050.4(BCKDHB):βc.348delβ(p.Asp117IlefsTer113) variant causes a frameshift, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000373 in 1,606,452 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (β β ). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: π 0.000013 ( 0 hom., cov: 31)
Exomes π: 0.0000028 ( 0 hom. )
Consequence
BCKDHB
NM_183050.4 frameshift, splice_region
NM_183050.4 frameshift, splice_region
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.690
Genes affected
BCKDHB (HGNC:987): (branched chain keto acid dehydrogenase E1 subunit beta) This gene encodes the E1 beta subunit of branched-chain keto acid dehydrogenase, which is a multienzyme complex associated with the inner membrane of mitochondria. This enzyme complex functions in the catabolism of branched-chain amino acids. Mutations in this gene have been associated with maple syrup urine disease (MSUD), type 1B, a disease characterized by a maple syrup odor to the urine in addition to mental and physical retardation and feeding problems. Alternative splicing at this locus results in multiple transcript variants. [provided by RefSeq, Jan 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 6-80167678-GA-G is Pathogenic according to our data. Variant chr6-80167678-GA-G is described in ClinVar as [Pathogenic]. Clinvar id is 457148.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BCKDHB | NM_183050.4 | c.348del | p.Asp117IlefsTer113 | frameshift_variant, splice_region_variant | 4/10 | ENST00000320393.9 | NP_898871.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BCKDHB | ENST00000320393.9 | c.348del | p.Asp117IlefsTer113 | frameshift_variant, splice_region_variant | 4/10 | 1 | NM_183050.4 | ENSP00000318351 | P1 | |
BCKDHB | ENST00000356489.9 | c.348del | p.Asp117IlefsTer113 | frameshift_variant, splice_region_variant | 4/11 | 1 | ENSP00000348880 | P1 | ||
BCKDHB | ENST00000369760.8 | c.348del | p.Asp117IlefsTer99 | frameshift_variant, splice_region_variant | 4/6 | 3 | ENSP00000358775 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151922Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
2
AN:
151922
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000159 AC: 4AN: 250924Hom.: 0 AF XY: 0.0000147 AC XY: 2AN XY: 135630
GnomAD3 exomes
AF:
AC:
4
AN:
250924
Hom.:
AF XY:
AC XY:
2
AN XY:
135630
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000275 AC: 4AN: 1454530Hom.: 0 Cov.: 31 AF XY: 0.00000276 AC XY: 2AN XY: 724066
GnomAD4 exome
AF:
AC:
4
AN:
1454530
Hom.:
Cov.:
31
AF XY:
AC XY:
2
AN XY:
724066
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151922Hom.: 0 Cov.: 31 AF XY: 0.0000270 AC XY: 2AN XY: 74186
GnomAD4 genome
AF:
AC:
2
AN:
151922
Hom.:
Cov.:
31
AF XY:
AC XY:
2
AN XY:
74186
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Maple syrup urine disease Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Laboratorio de Genetica e Diagnostico Molecular, Hospital Israelita Albert Einstein | Nov 10, 2022 | ACMG classification criteria: PVS1 very strong, PM2 supporting, PM3 strong, PP4 - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 06, 2023 | This sequence change creates a premature translational stop signal (p.Asp117Ilefs*113) in the BCKDHB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BCKDHB are known to be pathogenic (PMID: 16786533, 22593002). This variant is present in population databases (no rsID available, gnomAD 0.009%). This premature translational stop signal has been observed in individuals with maple syrup urine disease (PMID: 16786533, 26232051). ClinVar contains an entry for this variant (Variation ID: 457148). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Nov 07, 2021 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Sep 16, 2019 | Variant summary: BCKDHB c.348delA (p.Asp117IlefsX113) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory (eg. c.853C>T, p.Arg285X; c.970C>T, p.Arg324X). The variant allele was found at a frequency of 1.6e-05 in 250924 control chromosomes (gnomAD). c.348delA has been reported in the literature in compound heterozygous and homozygous individuals affected with Maple syrup urine disease (Couce_2015, Rodriguez-Pombo_2006). These data indicate that the variant may be associated with disease. Enzymatic activity in an individual homozygous for the variant was determined to be 14% and in an individual compound heterozygous for the variant and another variant was determined to be 1.3%. A ClinVar submitter (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. - |
Maple syrup urine disease type 1B Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | May 24, 2021 | - - |
Maple syrup urine disease type 1A Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Jan 12, 2024 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_AG_spliceai
Position offset: 6
Find out detailed SpliceAI scores and Pangolin per-transcript scores at